IS7268A - Chemically altered synthetic human growth hormone - Google Patents

Chemically altered synthetic human growth hormone

Info

Publication number
IS7268A
IS7268A IS7268A IS7268A IS7268A IS 7268 A IS7268 A IS 7268A IS 7268 A IS7268 A IS 7268A IS 7268 A IS7268 A IS 7268A IS 7268 A IS7268 A IS 7268A
Authority
IS
Iceland
Prior art keywords
growth hormone
human growth
chemically altered
synthetic human
altered synthetic
Prior art date
Application number
IS7268A
Other languages
Icelandic (is)
Inventor
F. Finn Rory
Liao Wei
R. Siegel Ned
Original Assignee
Pharmacia Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corporation filed Critical Pharmacia Corporation
Publication of IS7268A publication Critical patent/IS7268A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/61Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
IS7268A 2001-11-20 2004-05-17 Chemically altered synthetic human growth hormone IS7268A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33190701P 2001-11-20 2001-11-20
PCT/US2002/037270 WO2003044056A2 (en) 2001-11-20 2002-11-20 Chemically-modified human growth hormone conjugates

Publications (1)

Publication Number Publication Date
IS7268A true IS7268A (en) 2004-05-17

Family

ID=23295870

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7268A IS7268A (en) 2001-11-20 2004-05-17 Chemically altered synthetic human growth hormone

Country Status (25)

Country Link
EP (1) EP1453859A2 (en)
JP (2) JP2005525302A (en)
KR (2) KR20070072924A (en)
CN (1) CN1608079A (en)
AP (1) AP2004003050A0 (en)
AU (1) AU2002356990A1 (en)
BR (1) BR0214451A (en)
CA (1) CA2467731A1 (en)
CO (1) CO5580794A2 (en)
EA (2) EA200700431A1 (en)
EC (1) ECSP045114A (en)
GE (1) GEP20063860B (en)
HR (1) HRP20040448A2 (en)
HU (1) HUP0500997A2 (en)
IL (1) IL162031A0 (en)
IS (1) IS7268A (en)
MA (1) MA27544A1 (en)
MX (1) MXPA04004809A (en)
NO (1) NO20042182L (en)
OA (1) OA13063A (en)
PL (1) PL374354A1 (en)
RS (1) RS53104A (en)
TN (1) TNSN04090A1 (en)
WO (1) WO2003044056A2 (en)
ZA (1) ZA200403907B (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
US6956135B2 (en) 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US7041855B2 (en) 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
AU2002357806A1 (en) * 2001-12-11 2003-06-23 Sun Bio, Inc. Novel monofunctional polyethylene glycol aldehydes
PT3025726T (en) * 2002-01-18 2020-01-09 Biogen Ma Inc POLYALKYLENE POLYMER COMPOUNDS AND USES OF THE SAME
KR20050093856A (en) 2002-09-09 2005-09-23 넥타르 테라퓨틱스 에이엘, 코포레이션 Water-soluble polymer alkanals
EP1591467A1 (en) * 2002-09-09 2005-11-02 Nektar Therapeutics Al, Corporation Conjugate between a polyethylene glycol having a terminal alkanal group and a human growth hormone
US20040142870A1 (en) * 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
US20050281778A1 (en) * 2003-03-28 2005-12-22 Myung-Ok Park Human growth hormone conjugated with biocompatible polymer
JP2008502301A (en) * 2003-10-10 2008-01-31 ノボ ノルディスク アクティーゼルスカブ Peptide conjugation
US7524813B2 (en) 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
ES2642214T3 (en) * 2004-01-21 2017-11-15 Novo Nordisk Health Care Ag Conjugation of peptides by transglutaminase
KR20070042567A (en) * 2004-08-31 2007-04-23 파마시아 앤드 업존 캄파니 엘엘씨 Glycerol Branched Polyethylene Glycol Human Growth Hormone Conjugates, Methods for Making the Same and Methods for Using the Same
BRPI0519430A2 (en) * 2004-12-22 2009-02-10 Ambrx Inc modified human growth hormone
EP2399893B1 (en) 2004-12-22 2018-08-15 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
EP1836316A4 (en) * 2004-12-22 2009-07-22 Ambrx Inc Methods for expression and purification of recombinant human growth hormone
EP1850878A2 (en) 2005-02-10 2007-11-07 Novo Nordisk A/S C-terminally pegylated growth hormones
CA2604222A1 (en) 2005-04-18 2006-10-26 Novo Nordisk A/S Il-21 variants
US8293708B2 (en) 2005-08-30 2012-10-23 Novo Nordisk Health Care A/G Liquid formulations N-terminal serine of pegylated growth hormone
CN101400646A (en) * 2005-11-08 2009-04-01 Ambrx公司 Promoters for modifying unnatural amino acids and unnatural amino acid polypeptides
WO2007070659A2 (en) 2005-12-14 2007-06-21 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
BRPI0713963A2 (en) * 2006-07-07 2012-11-27 Novo Nordisk Healthcare Ag protein conjugates and methods for their preparation
CN101108895B (en) * 2006-07-19 2011-10-26 北京键凯科技有限公司 Polyglycol ethanal derivant and combo of medicament and the same
JP2010507382A (en) 2006-10-26 2010-03-11 ノヴォ ノルディスク アクティーゼルスカブ IL-21 mutant
CL2008002399A1 (en) * 2007-08-16 2009-01-02 Pharmaessentia Corp Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c.
US9840546B2 (en) 2008-04-03 2017-12-12 Biosteed Gene Expression Tech. Co., Ltd. Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof
MX344559B (en) 2008-04-29 2016-12-20 Ascendis Pharma As Pegylated recombinant human growth hormone compounds.
KR101104574B1 (en) * 2008-05-14 2012-01-11 성균관대학교산학협력단 Human Growth Hormone Chemically Modified with Polyethylene Glycol, Method of Preparation and Use thereof
AR072850A1 (en) * 2008-07-31 2010-09-22 Pharmaessentia Corp PEPTIDO-POLYMER CONJUGATES
MX2011000847A (en) 2008-08-06 2011-02-25 Novo Nordisk Healthcare Ag Conjugated proteins with prolonged in vivo efficacy.
RU2409669C9 (en) * 2008-08-18 2012-05-27 ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") Method for immobilising biologically active substance (bas) on carrier (versions) and bas-carrier conjugate produced by such methods
JP5766118B2 (en) * 2008-09-11 2015-08-19 ウェルズ ファーゴ バンク ナショナル アソシエイション Polymeric alpha-hydroxyaldehyde and ketone reagents and conjugation methods
MX2011007736A (en) 2009-01-22 2011-09-06 Novo Nordisk Healthcare Ag Stable growth hormone compounds.
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
MX337432B (en) 2009-12-15 2016-03-04 Ascendis Pharma As Dry growth hormone composition transiently linked to a polymer carrier.
RS59459B1 (en) 2010-01-22 2019-11-29 Novo Nordisk Healthcare Ag Growth hormones with prolonged in-vivo efficacy
MX338357B (en) 2010-01-22 2016-04-13 Novo Nordisk Healthcare Ag Stable growth hormone compounds.
KR20130115086A (en) * 2010-05-17 2013-10-21 세빅스 인코포레이티드 Pegylated c-peptide
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
EA019967B1 (en) * 2011-12-21 2014-07-30 Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") Polyethyleneglycol covalent conjugate with human growth hormone
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
JP6820841B2 (en) 2014-11-06 2021-01-27 ファーマエッセンティア コーポレイション Dosing regimen for pegged interferon
SG11201703870UA (en) 2014-11-18 2017-06-29 Ascendis Pharma Endocrinology Div As Novel polymeric hgh prodrugs
PT3220892T (en) 2014-11-21 2021-11-05 Ascendis Pharma Endocrinology Div A/S Long-acting growth hormone dosage forms
AU2016228555B2 (en) * 2015-03-11 2021-12-23 Nektar Therapeutics Conjugates of an IL-7 moiety and a polymer
NZ740534A (en) 2015-09-18 2019-07-26 Univ Miyazaki Long-acting adrenomedullin derivative
AU2020233198B2 (en) 2019-03-04 2025-05-15 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms with superior efficacy to daily somatropin
CN114539384B (en) * 2020-11-19 2024-09-06 江苏众红生物工程创药研究院有限公司 Pegylated long-acting growth hormone, preparation method and medical application thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
DK0458064T3 (en) * 1990-05-04 1998-04-27 American Cyanamid Co Stabilization of somatotropins by modifying cysteine residues
JPH06506217A (en) * 1991-03-18 1994-07-14 エンゾン,インコーポレーテッド Hydrazine-containing conjugates of polypeptides or glycopolypeptides and polymers
AU2147192A (en) * 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
DK0851925T3 (en) * 1995-09-21 2005-11-28 Genentech Inc Human Growth Hormone Variants
ES2297889T3 (en) * 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. DERIVATIVES OF HORMONE OF GROWTH AND RELATED PROTEINS.
CA2359345A1 (en) * 1999-01-14 2000-07-20 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
IL144361A0 (en) * 1999-01-29 2002-05-23 Hoffmann La Roche Gcsf conjugates
WO2001076639A2 (en) * 2000-04-06 2001-10-18 Pharmacia Corporation Chemically-modified myelopoietin conjugates
AU2002219021A1 (en) * 2001-01-11 2002-07-24 Maxygen Aps Variant growth hormone molecules conjugated with macromolecular compounds

Also Published As

Publication number Publication date
EA008505B1 (en) 2007-06-29
AP2004003050A0 (en) 2004-06-30
EA200700431A1 (en) 2008-02-28
CN1608079A (en) 2005-04-20
EP1453859A2 (en) 2004-09-08
RS53104A (en) 2006-10-27
JP2006321808A (en) 2006-11-30
PL374354A1 (en) 2005-10-17
KR20050044858A (en) 2005-05-13
BR0214451A (en) 2006-05-30
TNSN04090A1 (en) 2006-06-01
MXPA04004809A (en) 2004-08-11
NO20042182L (en) 2004-08-11
WO2003044056A2 (en) 2003-05-30
CO5580794A2 (en) 2005-11-30
OA13063A (en) 2006-11-10
JP2005525302A (en) 2005-08-25
GEP20063860B (en) 2006-06-26
ECSP045114A (en) 2004-07-23
HRP20040448A2 (en) 2006-02-28
WO2003044056A3 (en) 2003-08-21
EA200400565A1 (en) 2005-06-30
IL162031A0 (en) 2005-11-20
CA2467731A1 (en) 2003-05-30
MA27544A1 (en) 2005-10-03
KR20070072924A (en) 2007-07-06
HUP0500997A2 (en) 2007-11-28
ZA200403907B (en) 2007-12-27
AU2002356990A1 (en) 2003-06-10

Similar Documents

Publication Publication Date Title
IS7268A (en) Chemically altered synthetic human growth hormone
DK1344773T3 (en) growth hormone
AU2002342653A8 (en) Modified growth hormone
DE60108654D1 (en) HARVESTER
DE50210654D1 (en) Harvester
DK1440077T3 (en) SYNTHETIC HEPARINPENTASACCHARIDES
DE60133643D1 (en) artificial grass
FI20010694L (en) Implant
DE50209261D1 (en) mowing
NO20024890L (en) implant
DK1542716T3 (en) Growth hormone releasing peptides
FR2815535B1 (en) PEDICULAR IMPLANT
DK1333853T3 (en) Growth Factor Complex
DE60131102D1 (en) monofilament
DE60238111D1 (en) VISZERALFETTMESSER WITH TONOMETER
EP1401431A4 (en) HUMAN GROWTH HORMONE ANTAGONISTS
DE50209070D1 (en) seeder
FR2810231B1 (en) SYNTHETIC CORNEA
DE60232967D1 (en) OKULAR TISSUE GROWTH FACTOR-SIMILAR PROTEIN
FR2806309B1 (en) IMPLANT
DE60226191D1 (en) Harvester
HUP0402334A3 (en) Modified human growth hormone
FR2825281B1 (en) DRAIN AND ITS APPLICATOR
DE60200268D1 (en) single crystal growth
IS5999A (en) Bone growth factor